Doctronic has raised US$40m in series B funding, marking its third funding round in less than a year.
The round was co-led by Abstract and Lightspeed Venture Partners, with participation from existing investors Seven Stars, Union Square Ventures, Tusk Ventures and Mantis.
Last year, Doctronic secured a US$20m series A and US$5m from Union Square Ventures, bringing its total funding to US$65m.
Matt Pavelle, co-chief executive and co-founder of Doctronic, said: “Health systems see us as infrastructure, the digital front door that routes their patients efficiently and keeps care in-network.
“Payers see us as unlimited primary care at a predictable cost.
“This round lets us push further into academic medical centers, digital health platforms, and payers, while continuing to serve millions of consumers directly.”
The New York-based company offers a HIPAA-compliant, AI-powered doctor consultation platform that is accessible 24/7 and makes clinical decisions autonomously.
It answers users’ questions with medical explanations and asks clinical questions in response. The platform also offers access to licensed physicians through video visits for an insurance copay or for US$39 without insurance.
Doctronic said it will use the funds to expand into paediatrics and generate further partnerships with academic institutions, payers, digital health platforms and hospital systems.
In January, the state of Utah announced a partnership with Doctronic to enable its autonomous AI system to legally renew prescriptions for patients with chronic conditions.
Through the partnership, Doctronic, launched in 2023, became the first AI to legally prescribe routine refills using its autonomous AI platform.
The company said it is in talks with regulators and governments in other states to expand its AI prescription services beyond Utah.
Last year, proposed legislation was introduced in the US House of Representatives to allow AI and machine learning technology to prescribe drugs approved by the Food and Drug Administration autonomously.
The Prescription of Drugs by Artificial Intelligence or Machine Learning Technologies, or, if approved, the Healthy Technology Act of 2025, was sponsored by Rep. David Schweikert, R-Ariz.
If approved, the bill would recognise AI as a “practitioner licensed by law to administer such drugs”.
It was referred to the Committee on Energy and Commerce.
